Thibault Mahévas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Thibault Mahévas has a total of 291 co-authors. Here are the top co-authors by number of shared publications:
- Jean-David Bouaziz
Université Paris Cité, INSERM U1342, Institut de Recherche Saint‐Louis Paris France
15 shared publications - Marie Jachiet
Dermatology Department Saint Louis Hospital Paris France
10 shared publications Maxime Battistella
Pathology Department Hôpital Saint Louis, Assistance Publique‐Hôpitaux de Paris (AP‐HP) Paris France
8 shared publications- Martine Bagot
Department of Dermatology, Centre Coordinateur National du Réseau de Cancers Rares INCa Lymphomes Cutanés Hôpital Saint Louis, Assistance Publique ‐ Hôpitaux de Paris (APHP), Université Paris Cité Paris France
7 shared publications - Charles Cassius
Department of Dermatology, Hôpital Saint‐Louis, AP‐HP; INSERM U1342 Université Paris Cité Paris France
6 shared publications Estelle Charvet
Dermatology Department Hôpital Saint Louis, Assistance Publique‐Hôpitaux de Paris (AP‐HP) Paris France
6 shared publications
Latest Publications
- 2 June 2026
- Published by Elsevier in Annales de Dermatologie et de Vénéréologie
- Vol. 153 (3) , 103492
Successful use of thalidomide in treating metastatic Crohn’s disease
- 2 June 2026
- Published by Elsevier in Annales de Dermatologie et de Vénéréologie
- Vol. 153 (3) , 103492
Successful use of thalidomide in treating metastatic Crohn’s disease
- 13 April 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (10)
Papulonodular mucinosis associated lupus erythematosus: A case series and a literature review
- 13 April 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (10)
Papulonodular mucinosis associated lupus erythematosus: A case series and a literature review
- 10 November 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (7)
Impact of BMI and quality of life on dupilumab response in chronic prurigo: A cohort study
- 10 November 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (7)
Impact of BMI and quality of life on dupilumab response in chronic prurigo: A cohort study
- 7 March 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (10)
Efficacy and safety profile of anifrolumab in skin lesions of systemic lupus erythematosus
- 7 March 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (10)
Efficacy and safety profile of anifrolumab in skin lesions of systemic lupus erythematosus
- 12 October 2024
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 92 (2) , 329-332
Favorable prognosis of subcutaneous sarcoidosis: French cohort of 80 patients compared with dermal sarcoidosis
- 12 October 2024
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 92 (2) , 329-332
Favorable prognosis of subcutaneous sarcoidosis: French cohort of 80 patients compared with dermal sarcoidosis
- 13 August 2024
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (4)
Transcriptomic analysis of one patient with lupus skin lesions treated with anifrolumab
- 13 August 2024
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (4)
Transcriptomic analysis of one patient with lupus skin lesions treated with anifrolumab
- Open Access
- 31 July 2024
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (5) , 1011-1016
Plasma cell‐directed therapies induce profound clinical and durable responses in patients with severe or relapsed/refractory scleromyxedema
Background: Scleromyxedema (SM) is a rare skin disorder related to monoclonal gammopathy. High dose intravenous immunoglobulins (HDIVIg) are usually used as a frontline therapy with initial efficacy. However, some patients evolve with relapse, refractory state or severe extra‐cutaneous complications such as dermato‐neuro syndrome (DNS) or cardiac involvement.The objective of the study is to evaluate the use of anti‐plasma cell treatment in these patients in order to obtain a deep and durable dermatological and haematological response.Methods: We report here eight patients treated with HDIVIg together with anti‐plasma cell therapy including: lenalidomide and dexamethasone (n = 5); bortezomib, cyclophosphamide and dexamethasone (n = 1); daratumumab, lenalidomide and dexamethasone (n = 2).Results: Combination of HDIVIg with a treatment targeting the monoclonal component led to a high level of haematological remission and drastically improved skin response with an acceptable safety profile in all patients. Moreover, HDIVIg was reduced and stopped in 4 of the 7 patients who achieved complete remission.Conclusions: The association of lenalidomide and dexamethasone with HDIVIg could improve the treatment of relapsed or severe SM.
- 31 July 2024
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (5) , 1011-1016
Open AccessPlasma cell‐directed therapies induce profound clinical and durable responses in patients with severe or relapsed/refractory scleromyxedema
Background: Scleromyxedema (SM) is a rare skin disorder related to monoclonal gammopathy. High dose intravenous immunoglobulins (HDIVIg) are usually used as a frontline therapy with initial efficacy. However, some patients evolve with relapse, refractory state or severe extra‐cutaneous complications such as dermato‐neuro syndrome (DNS) or cardiac involvement.The objective of the study is to evaluate the use of anti‐plasma cell treatment in these patients in order to obtain a deep and durable dermatological and haematological response.Methods: We report here eight patients treated with HDIVIg together with anti‐plasma cell therapy including: lenalidomide and dexamethasone (n = 5); bortezomib, cyclophosphamide and dexamethasone (n = 1); daratumumab, lenalidomide and dexamethasone (n = 2).Results: Combination of HDIVIg with a treatment targeting the monoclonal component led to a high level of haematological remission and drastically improved skin response with an acceptable safety profile in all patients. Moreover, HDIVIg was reduced and stopped in 4 of the 7 patients who achieved complete remission.Conclusions: The association of lenalidomide and dexamethasone with HDIVIg could improve the treatment of relapsed or severe SM.